Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX- 124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
Thursday, May 23, 2024 BiopharmaWatch Research 1 min read
Key Takeaway: Werewolf Therapeutics announced that it will present updated data from its Phase 1/1b clinical trial of WTX-124. The trial evaluates WTX-124 both as a monotherapy and in combination with pembrolizumab for treating solid tumors. This presentation will occur at the 2024 ASCO Annual Meeting, showcasing the company's advancements in oncology.
Price reaction · baseline $4.99 (2024-05-23T17:57:00.000Z) · hit during market hours · clean, no other HOWL news in the window
day 0 close · peak
+3.4%
Market Sentiment Analysis
POSITIVE FACTORS
Werewolf Therapeutics is presenting updated data, indicating progress.
The trial involves a combination therapy, which may enhance treatment efficacy.
Presentation at a prestigious event like ASCO highlights the significance of the findings.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+25%
120-day peak, hindsight
Typical move
15%
average across 6 past catalysts
Lead asset
WTX-330
Phase 1 · Advanced or Metastatic Solid Tumors
Full Press Release Details
May 23, 2024
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX- 124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
WATERTOWN, Mass., May 23, 2024 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”)
Share this article:
facebook-icon
twitter-icon
linked-in-icon
Frequently Asked Questions
What is WTX-124?
WTX-124 is a therapeutic candidate being evaluated for treating solid tumors.
When will the data be presented?
The updated data will be presented at the 2024 ASCO Annual Meeting.
What is the significance of the ASCO meeting?
The ASCO meeting is a prestigious event for showcasing advancements in oncology.
What does Phase 1/1b trial mean?
Phase 1/1b trials assess safety, dosage, and preliminary efficacy of a treatment.